Joyzyme Group Limited (HKG:8622)

Market Cap	113.40M -49.1%
Revenue (ttm)	31.47M +11.5%
Net Income	-5.57M
EPS	-0.01
Shares Out	515.47M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	672,000
Open	0.2190
Previous Close	0.2190
Day's Range	0.2100 - 0.2300
52-Week Range	0.2030 - 0.7500
Beta	0.78
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 7, 2026

About Joyzyme Group

Joyzyme Group Limited, an investment holding company, engages in the research, production, and sale of male fertility in-vitro diagnostic (IVD) reagents in the People's Republic of China. The company provides biological reagents, including male fertility IVD reagents, parasite antibody detection reagents, and Epstein-Barr virus antibody detection reagent; healthcare products and supplements; and auxiliary reproductive supplies and equipment. The company sells its products directly to hospitals and medical institutions, as well as to distributor...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1992
• Employees: 98
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 8622

Financial Performance

In 2025, Joyzyme Group's revenue was 28.28 million, an increase of 11.53% compared to the previous year's 25.36 million. Losses were -5.01 million, 20.4% more than in 2024.

Financial numbers in CNY